Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Interest Expenses (2016 - 2025)

Northwest Biotherapeutics' Interest Expenses history spans 16 years, with the latest figure at $2.6 million for Q4 2025.

  • Quarterly results put Interest Expenses at $2.6 million for Q4 2025, up 6.35% from a year ago — trailing twelve months through Dec 2025 was $8.7 million (up 11.95% YoY), and the annual figure for FY2025 was $8.7 million, up 11.95%.
  • Interest Expenses for Q4 2025 was $2.6 million at Northwest Biotherapeutics, up from $2.6 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.6 million in Q4 2025 to a low of $807000.0 in Q2 2021.
  • The 5-year median for Interest Expenses is $1.6 million (2024), against an average of $1.6 million.
  • Peak annual rise in Interest Expenses hit 131.52% in 2021, while the deepest fall reached 71.05% in 2021.
  • Year by year, Interest Expenses stood at $1.2 million in 2021, then rose by 5.9% to $1.2 million in 2022, then rose by 1.72% to $1.2 million in 2023, then skyrocketed by 100.32% to $2.5 million in 2024, then grew by 6.35% to $2.6 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $2.6 million, $2.6 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.